A newly developed chelator can significantly reduce off-target toxicity in prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy, according to research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. By improving the bond between the radioactive metal ion and the PSMA-targeting antibody, the chelator can make PSMA therapy safer and more effective for patients.
Related Keywords
University Of Missouri , Missouri , United States , Lumiphore Berkeley , Carolyn Anderson , Journal Of Nuclear Medicine , Society Of Nuclear Medicine , Nuclear Medicine , Molecular Imaging Annual , Ellebracht Professor , Medicinal Chemistry ,
comparemela.com © 2020. All Rights Reserved.